Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low‐density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ESC Heart Fail
Autori principali: Miñana, Gema, Núñez, Julio, Bayés‐Genís, Antoni, Revuelta‐López, Elena, Ríos‐Navarro, César, Núñez, Eduardo, Chorro, Francisco J., López‐Lereu, Maria Pilar, Monmeneu, Jose Vicente, Lupón, Josep, Sanchis, Juan, Bodí, Vicent
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Original Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7083416/
https://ncbi.nlm.nih.gov/pubmed/31903686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12533
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi